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Abstract
Purpose Achilles tendon ruptures are devastating and
recover slowly and incompletely. There is a great demand
for biomolecular therapies to improve recovery, yet little is
understood about growth factors in a healing tendon. Here,
the role of growth factors during tendon healing in a rat
model and their reaction to single and multiple growth
factor treatment are explored.
Methods Rat tendons were transected surgically and
resutured. The expression of bFGF, BMP-12, VEGF and
TGF-b1 was assessed by immunohistochemical analysis
one to 8 weeks after surgery. Paracrine effects of TGF-b1
or BMP-12 added by adenoviral transfer, as well as the
effect of autologous conditioned serum (ACS) on growth
factor expression, were evaluated.
Results bFGF, BMP-12 and VEGF expression was highest
1 week after transection. bFGF and BMP-12 declined during
the remaining period whereas VEGF expression persisted.
TGF-b1 expression dramatically increased after 8 weeks.
ACS treatment increased bFGF (P = 0.007) and BMP-12
(P = 0.004) expression significantly after 8 weeks. Also
overall expression of bFGF, BMP-12 and TGF-b1 regardless
of time point was significantly greater than controls with ACS
treatment (P \ 0.05). Both BMP-12 and TGF-b1 treatments
had no significant effect. No effect was observed in VEGF
with any treatment.
Conclusion bFGF, BMP-12, VEGF and TGF-b1 are dif-
ferentially expressed during tendon healing. Additional
BMP-12 or TGF-b1 has no significant influence, whereas
ACS generally increases expression of all factors except
VEGF. Staged application of multiple growth factors may
be the most promising biomolecular treatment.
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Abbreviations
ACS Autologous conditioned serum
bFGF Basic fibroblast growth factor, a.k.a. FGF-2
BMP Bone morphogenic protein
CDMP Cartilage-derived morphogenic protein
GDF Growth and differentiation factor
IGF-1 Insulin-like growth factor 1
PDGF Platelet-derived growth factor
TGF-b1 Transforming growth factor beta 1
VEGF Vascular endothelial growth factor
Introduction
Tendon ruptures and tears are common injuries that heal
slowly and are often treated surgically. However, clinical
outcomes are not always satisfactory [21]. Growth factors
play an important role in tendon healing [15], and there is
increasing confidence that accelerated and improved heal-
ing may be achievable by biological intervention.
The physiological course of tendon healing with an empha-
sis on growth factor expression has been studied for various
models of tendon pathology, including rotator cuff tears
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[10, 23, 32, 40] and Achilles tendon ruptures in a rat model
[3, 8, 9, 19, 29]; in vitro studies have used tenocyte cultures [6].
There have been a number of experiments in which
recombinant growth factors have been applied in attempts
to accelerate tendon healing in an animal model, but most
have used only a single factor and results have been vari-
able. Experiments designed to study the endogenous
expression of growth factors have measured expression
over only a few days or even just at a single time point.
Thus, the natural expression of growth factors over time
and the influence of growth factors added to promote ten-
don healing remains unclear [15, 22].
To address this issue, a rat model of acute traumatic
Achilles tendon rupture without tendinopathy was chosen
and four growth factors—basic Fibroblast growth Factor
(bFGF), bone morphogenic factor 12 (BMP-12), vascular
endothelial growth factor (VEGF) and transforming growth
factor beta (TGF-b1)—that have an established and promi-
nent role during tendon healing [22, 24] were measured.
Previous experiments have shown that basic fibroblast
growth factor (bFGF, FGF-2) stimulates proliferation and
thereby increases the cellularity of a healing tendon [1, 10,
36]. Bone morphogenic factor 12 (BMP-12, a.k.a. CDMP-3
or GDF-7) is important for tenoblast and fibroblast differ-
entiation [5, 19, 23, 32], and vascular endothelial growth
factor (VEGF) plays an essential role in angiogenesis [26,
40]. Transforming growth factor beta one (TGF-b1) is
known to influence the healing of fibrous tissues including
tendons. It is secreted by infiltrating macrophages and
platelets and is known to stimulate proliferation and matrix
organisation [2, 9, 13, 16, 27].
The hypothesis was that growth factors would be elevated
at the beginning of tendon healing and would then gradually
decrease as healing progressed. Stimulating this process with
exogenous growth factors would lead to a prolonged
endogenous expression of the growth factors over time.
To verify this either bone morphogenic factor 12 (BMP-
12) as a specific inductor of tendon and ligament tissue,
transforming growth factor beta (TGF-b1) as a treatment
with diverse effects or autologous conditioned serum
(ACS) as a representative of biological treatment with
multiple growth factors was added.
Materials and methods
Rat Achilles tendon healing model
Approval for all animal procedures was obtained before-
hand from the local Institutional Animal Care and Use
Committee of Harvard Medical School (Boston, MA,
USA). Sixty male adult Sprague-Dawley rats (weight
400–425 g, [10 weeks old) were used.
Fifteen animals per group were used for natural
expression of growth factors, controls, BMP-12, TGF-b1
and ACS groups. For each group, 3 animals each were
euthanised after 1, 2, 4 and 8 weeks. The unoperated
contralateral tendons of the animals not treated were used
to establish a baseline for the stainings.
Animals were placed under general anaesthesia with
isoflurane. The right hind leg was shaved and disinfected
with Betadine. After placement on a warm sterile field, a
3-cm incision was made above the right Achilles tendon.
The peritendon was opened and the Achilles tendon cut at a
right angle to the collagen fibres, creating a 5-mm gap
proximal to the calcaneal insertion. The plantaris tendon
was transected, preventing a splinting phenomenon.
In animals used for examination of endogenous
expression of growth factors and animals in the control and
ACS group, Achilles tendon, peritendon and skin were
sutured back together.
For animals in groups with BMP-12 or TGF-b1 treat-
ment, the transfected muscle grafts were placed with two
single stitches around the side of tendon injury after end-to-
end suture repair.
After regaining consciousness, the rats received bupr-
enorphine injections twice daily for 2 days.
Growth factors
BMP-12 or TGF-b1 cDNA was transferred to 4-mm round
muscle flaps harvested from a donor rat by gene transfer
using recombinant adenovirus vectors as described previ-
ously [19]. In short, serotype 5 recombinant adenoviral
vector was used, recombinant adenoviruses (Ad.BMP-12
or Ad.TGF-b1) were propagated in 293/Cre8 cells and
muscle grafts incubated with particles in DMEM medium
with 5% foetal bovine serum for 24 h before implantation.
Expression of BMP-12 and TGF-b1 has been found to be
increased 4–7 days after transfection [19].
ACS was used from a previous study as described [20].
In short, pooled rat blood was incubated for 9 h at 37C in
Orthokine syringes (Orthogen AG, Duesseldorf, Germany)
containing glass beads. Samples were then centrifuged and
frozen at -20C. For injection, aliquots were thawed on ice
and allowed to reach room temperature. A volume of
170 ll of ACS were injected once every 24 h for 3 days
directly into the area of the sutured repair using a 1-ml
insulin syringe. According to previous studies, ACS
contains increased levels of TGF-b1, bFGF and VEGF
compared to basal serum concentrations, as well as
inflammatory and anti-inflammatory cytokines. However,
Platelet-derived growth factor-BB (PDGF-BB) in rat
derived ACS and insulin-like growth factor 1 (IGF-1) in
human derived ACS were not substantially increased
[20, 37].
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Immunohistochemical analysis
Animals were placed under general anaesthesia with isoflu-
rane and asphyxiated with CO2. To harvest the whole muscle–
tendon–bone units a 5-cm incision was made from below the
knee down to the plantar fascia of the foot. Muscle–tendon–
bone units were explanted by transection of the middle part of
the gastrocnemius muscle and of the calcaneus.
The tendons were immediately placed in 4% buffered
formalin (pH 7.4) for 24 h, dehydrated and embedded in
paraffin wax. Endogenous peroxidase was blocked by
30-min incubation in 1% hydrogen peroxide in phosphate-
buffered saline (PBS). After washing in PBS, sections were
incubated for 1 h with 2% powdered milk in PBS to block
nonspecific protein binding. Sections were incubated with
the primary antibody over night at 4C, followed by three
5-min washes. For amplified detection with biotin–avidin–
peroxidase, sections were incubated with biotinylated
secondary antibody (rabbit anti-mouse biotin label or goat
anti rabbit biotin label, Dako, Denmark) for 30 min at
room temperature, washed three times with PBS and
incubated with avidin-biotinylated-peroxidase complex
(Vectastain ABC Kit Elite Standard, Vector, CA, USA) for
30 min at room temperature. This was followed by three
5-min washes with PBS. Substrate (solution with Tris,
peroxide and 3,3 Diaminobenzidine tablets, Sigma,
Munich) was added for 5 min. Sections were washed in tap
water three times and stained with haematoxylin and eosin.
Primary antibodies used were against bFGF (rabbit poly-
clonal; Abcam, Cambridge UK), BMP-12 (rabbit poly-
clonal; AbD Serotec, Oxford, UK), VEGF (mouse
monoclonal; Abcam, Cambridge, UK) and TGF-b1 (rabbit
polyclonal; Santa Cruz, CA, USA).
Histological scoring was supported by digital image
analysis (Image-Pro Plus, Media Cybernetics, Silver
Spring, MD, USA). Samples were taken from 5 distinct
locations, including the central part of the rupture, the left
and right borders, borders towards the muscle insertion and
the calcaneal insertion. Scores of the 5 sections were then
averaged to a whole score for the tendon.
The immunoreactive score used is widely accepted for
quantification of immunohistological stainings [4, 14, 28,
30, 35, 39]. The characterisation of relative amount and
location of the protein of interest and the high sensitivity
are of great advantage. The score was calculated by
assigning points for overall staining (1 for no staining to 4
for strong staining) and for overall stained cells (1 for no
cells to 5 for over 80% of cells) and multiplying both to a
general score. Sections were scored by two independent
blinded observers with high inter-observer reliability
(Spearman’s correlation coefficient 0.86). Scores also
correlated strongly with digital image analysis of overall
stained area (coefficient 0.85).
Statistical analysis
Analysis of variance (ANOVA) was performed on time
courses and differences between groups. Where ANOVA
was significant, multiple comparisons were performed with
the Tukey-HSD post hoc test. Results were considered sig-
nificant with a P-value of\0.05. Statistics, plots of means
and standard deviations were produced with R v. 2.10.1.
Results
Natural course of growth factor expression
during tendon healing
bFGF, BMP-12, TGF-b1 and VEGF were detected in all
samples and displayed clearly distinct time courses of
expression (Fig. 1), thereby validating the immunohisto-
logical scoring performed.
Expression levels of bFGF (P = 0.012) and BMP-12
(P = 0.008) were significantly higher 1 week after transec-
tion compared to unoperated rat Achilles tendons whereas no
significant difference was observed for TGF-b1 and VEGF.
After 2, 4 and 8 weeks bFGF expression was close to the
expression found in unoperated tendon. Similarly, BMP-12
expression decreased rapidly over time. From 2 weeks
onwards, expression of BMP-12 was similar to the expression
observed in untreated tendons.
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Fig. 1 Immunoreactive scores for primary antibodies against bFGF,
BMP-12, VEGF and TGF-b1 at different time points after tendon
transection. The scores are plotted as means. Every point in the plot
represents the mean value of 3 samples for the respective time point.
Points at ‘0 weeks’ represent the mean score of normal tendon.
P-values refer to the difference to normal tendon. See text for further
description
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VEGF expression was elevated after 1 week, decreasing
to normal at week 2 and slightly increasing to 3 points at
weeks 4 and 8.
Interestingly, TGF-b1 showed a different pattern of
expression compared to the other three growth factors.
It was elevated at week 1 and subsequently declined to
the level of normal tendon at weeks 2 and 4. However,
expression increased again after 8 weeks. Changes in TGF-
b1 staining scores more strongly reflected the number of
stained cells at each time point. Representative histological
images are shown in Fig. 2.
Auto- and paracrine effects of BMP-12, TGF-b1 or ACS
on growth factor expression
ACS had the greatest effect on growth factor expression. It
increased bFGF significantly after 8 weeks compared to
controls (P = 0.007) and BMP-12 (P = 0.004). A nearly
significant elevation of bFGF was also observed with ACS
in week 4 compared to BMP-12 (P = 0.074) and TGF-b1
(P = 0.084). Comparing the expression of BMP-12, TGF-
b1 and VEGF between groups at single time points did not
yield any significant differences (Figures 3, 4, 5, 6).
Overall bFGF expression regardless of time point was
significantly greater in the ACS group compared to con-
trols and the BMP-12 and TGF-b1 groups (all P \ 0.002).
Overall BMP-12 expression was also greater in the ACS
group compared to controls and the BMP-12 and TGF-b1
groups (all P \ 0.05). Overall TGF-b1 expression was
greater in the ACS group compared to controls and the
TGF-b1 group (all P \ 0.05). There was no significant
difference between groups for the overall expression of
VEGF.
Discussion
The most important findings of the present study were the
distinct time courses of the measured growth factors and
their increase with ACS stimulation. Affirming the initial
Fig. 2 Representative immunohistochemical sections of tendons 1, 2, 4 and 8 weeks after tendon rupture using antibodies against bFGF,
BMP-12, VEGF and TGF-b1. The grey bar in the top left image represents 100 lm
1910 Knee Surg Sports Traumatol Arthrosc (2012) 20:1907–1914
123
hypothesis, the expression of bFGF, BMP-12, VEGF and
TGF-b1 was elevated in the 1 week of healing, possibly in
response to the inflammation after rupture. As the healing
progressed, each growth factor followed a slightly different
path, most likely interacting with the effects of other
growth factors. BMP-12 and bFGF expression both
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Fig. 3 Expression of bFGF over time as measured by immunoreac-
tive score. For weeks 1, 2, 4 and 8, grey boxes indicate the mean
values of immunoreactive scores for controls and groups stimulated
with either ACS (?ACS), TGF-b1 (?TGF) or BMP-12 (?BMP) as
indicated. Whiskers indicate the upper standard deviation; the lower
symmetrical interval is omitted for reasons of clarity and compre-
hensibility. Brackets with stars on top indicate significant pairings,
**P \ 0.01
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Fig. 4 Expression of BMP-12 over time as measured by immunoreac-
tive score. For weeks 1, 2, 4 and 8, grey boxes indicate the mean values of
immunoreactive scores for controls and groups stimulated with either
ACS (?ACS), TGF-b1 (?TGF) or BMP-12 (?BMP) as indicated.
Whiskers indicate the upper standard deviation; the lower symmetrical
interval is omitted for reasons of clarity and comprehensibility
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Fig. 5 Expression of TGF-b1 over time as measured by immunoreactive
score. For weeks 1, 2, 4 and 8 grey boxes indicate the mean values of
immunoreactive scores for controls and groups stimulated with either
ACS (?ACS), TGF-b1 (?TGF) or BMP-12 (?BMP) as indicated.
Whiskers indicate the upper standard deviation; the lower symmetrical
interval is omitted for reasons of clarity and comprehensibility
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Fig. 6 Expression of VEGF over time as measured by immunoreactive
score. For weeks 1, 2, 4 and 8, grey boxes indicate the mean values of
immunoreactive scores for controls and groups stimulated with either
ACS (?ACS), TGF-b1 (?TGF) or BMP-12 (?BMP) as indicated.
Whiskers indicate the upper standard deviation; the lower symmetrical
interval is omitted for reasons of clarity and comprehensibility
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declined rapidly after the 1 week of healing, possibly
because inflammation was resolving at this stage. After
2–4 weeks, both growth factors approached their basal
expression levels.
TGF-b1 showed an initially high expression, declined
rapidly to normal concentrations and increased again
strongly in week 8, probably reflecting remodelling and scar
formation in the late stages of tendon healing. VEGF
expression was initially higher than normal and remained
above normal for the entire 8-week period. This may reflect
the importance of neoangiogenesis in tendon healing.
However, it is surprising that VEGF expression did not
decline at the end of this period because it coincides with an
elevated expression of TGF-b1, which has been reported to
suppress VEGF expression in tendon [8]. Also, from a tissue
architecture point of view, a decrease in neoangiogenesis due
to scar formation after 8 weeks might be expected [34].
In contrast to the second hypothesis, ACS displayed the
greatest effect on the endogenous expression of growth fac-
tors, while the addition of TGF-b1 or BMP-12 did not affect or
seemed to even decrease their expression. This may indicate a
reactive suppression due to the addition of BMP-12 or TGF-
b1 and may signify that addition of a single growth factor
cannot emulate the complex interactions of healing.
According to previous studies, ACS contains increased
levels of TGF- b1, bFGF and VEGF, as well as inflam-
matory and anti-inflammatory cytokines [20, 37].
Schippinger found no significant systematic influence
and no significant increase of IGF-1 using ACP (autolo-
gous conditioned plasma) after intramuscular application
[31]. Due to the fast absorption and degradation of the
cytokines, it was not expected that the dosage of ACS used
would have any generalised effect or an effect on the
contralateral tendon.
Limitations of this study were the use of transected
Achilles tendons without tendinopathy, the time of follow-
up and the restricted number of growth factors to eminent
key factors during tendon healing.
However, it was not intended to mimic the pathophys-
iology of human tendinopathy, the most frequent and
devastating disease leading to Achilles tendon ruptures [17,
34]. Instead, the study concentrated on transected Achilles
tendons that simulate a rupture in an otherwise healthy
tendon in order to illuminate the normal process of tendon
healing and to investigate the effect of additional growth
factors. This knowledge is crucial because it allows one to
approach the pathologically changed Achilles tendon with
more understanding of the pathological differences.
The time points for examination of the growth factor
expression were chosen based upon a similar study of
rotator cuff healing in rats [38] and reflect the time course
of the different phases of tendon healing, namely early
inflammation, reorganisation and late tissue remodelling.
Tendon ruptures lead to a considerable loss of function
of the injured extremity. During healing, the ruptured
tendon forms a regenerate within the first few weeks, yet
despite intensive remodelling over the following months a
complete regeneration of the tendon is never achieved [15].
Tendon healing is a complex and highly regulated process
that is initiated, sustained and terminated by a large variety
of biomolecular and biomechanical stimuli [11, 22]. The
scar tissue that is formed is mostly mechanically inferior
and cannot perform as well as a normal tendon [3, 19, 25].
It is established that patients profit from an early func-
tional therapy after Achilles tendon repair (e.g., [7, 33]).
Current development of biomolecular therapies aims to
further improve healing results [33]. Current trends may
lead to a gross oversimplification of the biological pro-
cesses and complex interactions between growth factors in
a healing tendon.
Based on the results of the present study, staged appli-
cation of different growth factors is likely to have a greater
effect than the application of a single growth factor at one
time point, a conclusion independently favoured by Molloy
et al. [22] and Oliva et al. [24]. ACS provides a convenient
means of applying multiple, autologous growth factors.
Several studies have shown its beneficial effect on the
healing tendon in rats, both in healing time and resulting
mechanical properties of the healed tendon [12, 18, 20].
Further studies may determine the right dosage and inter-
vals for an optimal therapy.
In view of a possible clinical application of biological
augmentation of tendon healing in man, there is no doubt about
the improvement by biological intervention. However, any
treatment aiming to mimic the natural biological process
should not focus on a single growth factor. Considering the
highly complex process of healing and the influence of exog-
enous cytokines on endogenous growth factors, a truly prac-
tical treatment will require much development. Nevertheless,
the future of growth factor based therapies is promising.
Conclusion
Tendon healing involves the coordinated, interactive medi-
ation of many growth factors. The four endogenous growth
factors studied here showed different expression patterns
during tendon healing and were differentially affected by the
exogenous application of BMP-12, TGF-b1 and ACS.
The present study suggest that the 1 week of tendon
healing is a crucial period of growth factor stimulation and
that ACS has the greatest influence on later expression
especially of bFGF and BMP-12. Future research should
focus on the complex interactions—synergism or antago-
nism—of growth factors in order to create a solid basis for
biomolecular treatment.
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